| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/04/2005 | US6838472 Substituted urea retinoid agonists |
| 01/04/2005 | US6838471 Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
| 01/04/2005 | US6838470 Antiischemic agents; brain disorders; cardiovascular disorders |
| 01/04/2005 | US6838469 Pharmaceutical composition that exhibits reduced side-effects comprising O-(3-piperidino-2-hydroxy-1-propyl)nicotinic acid amidoxime and a pyrimidine derivative with known antitumor activity |
| 01/04/2005 | US6838468 4-(phenyl-piperdin-4-ylidene methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders |
| 01/04/2005 | US6838467 Dosing regimen |
| 01/04/2005 | US6838466 Compounds for the treatment of inflammatory disorders |
| 01/04/2005 | US6838465 N-acyltetrahydroisoquinoline derivatives |
| 01/04/2005 | US6838464 Inhibitor of cyclin-dependent kinase |
| 01/04/2005 | US6838461 Psychological disorders; schizophrenia; Alzheimer's disease; Parkinson's disease; Huntington's disease; cardiovascular disorders; hypotensive agents; side effect reduction |
| 01/04/2005 | US6838460 Substituted phenylamidines medicaments containing said compounds and method for production thereof |
| 01/04/2005 | US6838459 7-alkyl-and cycloalkyl-substituted imidazotriazinones |
| 01/04/2005 | US6838458 5-(alkylidene-cycloalkyl)-and 5-(alkylidene-heterocyclyl)-pyrazoles |
| 01/04/2005 | US6838457 Fused heteroaryl derivatives |
| 01/04/2005 | US6838456 Condensed pyridoindole derivatives |
| 01/04/2005 | US6838454 Carboxylic acid substituted heterocycles, derivatives thereof and methods of use |
| 01/04/2005 | US6838453 Therapy for osteoporosis |
| 01/04/2005 | US6838452 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| 01/04/2005 | US6838451 Mixture of glucosamine, linoleic acid and ascorbic acid; bone diosrders, antiarthritic agents, antiinflammatory agents |
| 01/04/2005 | US6838449 Ophthalmic compositions containing galactomannan polymers and borate |
| 01/04/2005 | US6838448 Mixture with electrolyte and antibiotic; storage before surgery |
| 01/04/2005 | US6838446 Anticancer agents; genetic engineered enzyme |
| 01/04/2005 | US6838443 Parasiticides |
| 01/04/2005 | US6838442 Administering to said subject a jointly effective amount of a glucose reabsorption inhibitor; administering jointly effective amount of an retinoid-X receptor modulator for therapy of diabetes or Syndrome X |
| 01/04/2005 | US6838437 Inactivation resistant factor VIII |
| 01/04/2005 | US6838436 Osteoporosis, bone fractures, oral diseases; administering a protein |
| 01/04/2005 | US6838253 Using an enzyme inhibitor of 11 beta -reductase; administering carbenoxolone |
| 01/04/2005 | US6838252 Inhibitors of proteasomal activity for stimulating hair growth |
| 01/04/2005 | US6838249 Identifying transport protein modulator using gabapentin (GBP) as a transfer/fluid flow indicator; anticonvulsant; neuropathic pain |
| 01/04/2005 | US6838248 Detecting cancerous and precancerous cells; obtain tissue sample, incubate wih tetrakis dyes, rince and remove unbound dye, detect fluorescence, fuorescence indicates cancerous or precancerous cells |
| 01/04/2005 | US6838096 Black soybean polysaccharides |
| 01/04/2005 | US6838095 Substantially non-colloidal solution made by combining ingredients comprising (a) water; (b) a source of free silver ions; and (c) a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent. |
| 01/04/2005 | US6838094 Tablet containing a coated core |
| 01/04/2005 | US6838093 System for osmotic delivery of pharmaceutically active agents |
| 01/04/2005 | US6838090 Water-insoluble drug delivery system |
| 01/04/2005 | US6838085 DNA immunization against Chlamydia infection |
| 01/04/2005 | US6837696 Apparatus for manufacturing dosage forms |
| 01/04/2005 | CA2350854C 1,4-dihydropyridine derivatives and methods of producing the same |
| 01/04/2005 | CA2340999C 5-arylindole derivatives |
| 01/04/2005 | CA2308513C Method and composition for delivering zinc to the nasal membrane |
| 01/04/2005 | CA2283509C Novel bicyclonucleoside and oligonucleotide analogue |
| 01/04/2005 | CA2255637C Conjugates of cis-docosahexaenoic acid and paclitaxel |
| 01/04/2005 | CA2251563C Method for maintaining an existing level of body fat and/or body weight |
| 01/04/2005 | CA2250929C 4-[(thien-2-yl)methyl]imidazole derivatives having alpha2-adrenoceptor agonistic activity |
| 01/04/2005 | CA2242015C New chromene derivatives, the procedure for preparing them and the pharmaceutical compounds that contain them |
| 01/04/2005 | CA2217322C Inhibition of complement pathway by sea cucumber fractions |
| 01/04/2005 | CA2186015C Nicotinic acid derivatives and herbicides |
| 01/04/2005 | CA2151730C New crystalline form of a vitamin d analogue |
| 01/04/2005 | CA2148827C Novel 3,3-diphenylpropylamines, their use and preparation |
| 01/04/2005 | CA2139725C Endoparasiticidal compositions |
| 01/04/2005 | CA2106897C Use of substituted 1,2,4-oxadiazole derivatives for combating endoparasites, new substituted 1,2,4-oxadiazole derivatives, and processes for their preparation |
| 01/04/2005 | CA2102072C Combination preparation containing flupirtin and morphine for the treatment of pain and the prevention of morphine dependence |
| 01/04/2005 | CA2093076C 2- and 3-amino and azido derivatives of 1,5-iminosugars |
| 01/02/2005 | WO2006125451A1 Hydroxyalkylamides |
| 01/02/2005 | CA2530195A1 Hydroxyalkylamides |
| 01/01/2005 | CA2472846A1 Methods for assessing and treating leukemia |
| 12/30/2004 | US20040268426 P2Y4 receptor transgenic and knockout non-human mammals |
| 12/30/2004 | US20040268425 use to treat glycosaminoglycan associated pathologies such as eye disorders or tumors; sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes; transgenic animals; dosage forms |
| 12/30/2004 | US20040267032 Process for recovering value-added products from pulping soap |
| 12/30/2004 | US20040267028 Such as 2-amino-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-cyclohexyl-1H-pyrrole-3-carboxamide hydrochloride |
| 12/30/2004 | US20040267025 Compounds for the treatment of metabolic disorders |
| 12/30/2004 | US20040267022 Amino alcohols; HIV protease inhibitors; acquired immune deficiency syndrome |
| 12/30/2004 | US20040267016 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) |
| 12/30/2004 | US20040267015 Bactericides |
| 12/30/2004 | US20040267012 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 12/30/2004 | US20040267010 For therapy of central nervous system disorders |
| 12/30/2004 | US20040267004 nucleic acid that binds to high mobility group protein-I (HMG-I), and causes presenilin-2 gene exon 5-lacked type aberrant splicing by the association with the HMG-I protein; an inhibitor for inhibiting a binding between protein-nucleic acid caused by aberrant splicing; drug screening; antisense agents |
| 12/30/2004 | US20040266997 impurities which may be produced during storage and/or synthesis of azithromycin; use in determining azithromycin purity or stability by assaying for said degradation product; formulation of high purity |
| 12/30/2004 | US20040266888 Composition for treatment of infections of humans and animals |
| 12/30/2004 | US20040266884 Compounds for blocking androgen receptors |
| 12/30/2004 | US20040266883 Preventing, treating, or alleviating symptoms of any disease or clinical condition which condition is at least partly the result of a defect in the cystic fibrosis transmembrane conductance regulator by administering a composition comprising at least two curcuminoids; cystic fibrosis |
| 12/30/2004 | US20040266882 Administering chemotherapeutically effective amount of at least one chemotherapeutic agent and a chemosensitizing effective amount of at least one 3-aryloxy-3-phenylpropylamine such as 3-(p-isopropoxyphenoxy)-3-phenylpropylamine methanesulfonate; advantageous in treatment of multidrug resistance cancer |
| 12/30/2004 | US20040266881 Acetamidobenzamide compounds for neurodegenerative disorders |
| 12/30/2004 | US20040266880 Preparation for preventing or treating pruritic symptoms, which comprises a prostaglandin or a pharmaceutically acceptable salt thereof as an effective ingredient; effective in eliminating the itch sensation due to atopic symptoms |
| 12/30/2004 | US20040266879 Certain ethers of probucol, and their pharmaceutically acceptable salts or prodrugs, are useful for increasing circulating high density lipoprotein cholestrol |
| 12/30/2004 | US20040266878 in polymorphic Form A free of other polymorphic forms, used as an antiallergen to treat, e.g., bronchial asthma |
| 12/30/2004 | US20040266877 Stable liquid oral dosage pharmaceutical composition, comprising at least one thyroid hormone, 40% to 96% of ethanol by volume, a pH adjusting agent so that measured pH of composition is 9 to 12, and 4% to 50% water by volume; accurately delivers small doses of thyroid hormone; long shelf life |
| 12/30/2004 | US20040266876 Method for preventing and treating visceral pain and gastrointestinal disorders |
| 12/30/2004 | US20040266875 Method for treatment and/or prophylaxis |
| 12/30/2004 | US20040266874 Contains, as active ingredient, arachidonic acid and/or a compound having arachidonic acid as a constituent fatty acid and, particularly, an alcohol ester of arachidonic acid or a triglyceride, phospholipid or glycolipid in which all or a portion of constituent fatty acids are arachidonic acid |
| 12/30/2004 | US20040266873 1-butane acid derivatives pharmaceutical compositions containing said derivatives and the use thereof |
| 12/30/2004 | US20040266872 Therapeutic compositions |
| 12/30/2004 | US20040266871 Methods for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons |
| 12/30/2004 | US20040266870 Inhibitors of the chemotactic activation induced by the fraction C5a of complement and from other chemotactic proteins (chemokines) that y activate a 7-transmembrane-domain receptor; psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, fibrosis; antiischemic agents |
| 12/30/2004 | US20040266869 Novel medicament compositions based on anticholinesterase drugs and on ciclesonides |
| 12/30/2004 | US20040266868 Triterpenoid derivatives |
| 12/30/2004 | US20040266867 2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-tert-butylaminoethanol hydrochloride; treating asthma and bronchitis |
| 12/30/2004 | US20040266866 Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
| 12/30/2004 | US20040266865 Use of pelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP 1 activity; use in treatment or prevention of an immune, inflammatory, or neoplastic condition or disorder |
| 12/30/2004 | US20040266864 Possess potent serotonin reuptake inhibitory activity, with minimal inhibitory effects on the reuptake of other known monoamines, e.g., norepinephrine or dopamine; also useful for treating or preventing other CNS disorders, cerebrovascular or vascular dysfunctions, sexual dysfunctiions, eating disorders |
| 12/30/2004 | US20040266863 Use of (11beta,17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder |
| 12/30/2004 | US20040266861 Administering a therapeutically effective amount of a compound which is a cannabinoid receptor agonist, a pharmaceutically acceptable salt of the compound, an isomer of the compound, or a pharmaceutically acceptable salt of the isomer |
| 12/30/2004 | US20040266860 Dihydroartemisinin and dihydroartemisitene dimers as anti-cancer and anti-infective agents |
| 12/30/2004 | US20040266858 Comprising water and 0.001 to 30% by weight of alpha -lipoic acid or a derivative thereof based on total weight of solution and having ph of 0.0-6.5; use in pharmaceutical, cosmetic or dietary products, in particular within framework of a supplementary or combination therapy or as solution for infusion |
| 12/30/2004 | US20040266857 11,12-dehydro-naphtho[1,2-b]thioxane-9,10-dione derivatives; antiproliferative agents; psoriasis, cancer |
| 12/30/2004 | US20040266855 Effective against Src family; cancer, osteoporosis |
| 12/30/2004 | US20040266851 Modulation using aromatic excitatory amino acid |
| 12/30/2004 | US20040266846 Formulations in carriers that increase expression or activity of proapoptotic Bcl-2 family members; cancer |
| 12/30/2004 | US20040266844 Antimicrobial and radioprotective compounds |
| 12/30/2004 | US20040266843 Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) |